- ICH GCP
- Реестр клинических исследований США
- Клиническое испытание NCT00262314
Prospective, Open-label Tolerability and Safety Monitoring Study of Novantrone in a Selected Cohort of Multiple Sclerosis Patients (RENEW)
Обзор исследования
Статус
Условия
Подробное описание
This phase IV, multicenter, prospective, open-label tolerability and safety monitoring study will enroll a select cohort of 500 multiple sclerosis patients receiving commercially available Novantrone®. The patients will be assessed every 3 months during treatment followed by annual assessment for a total of five (5) years.
The select cohort of MS patients enrolled will have secondary (chronic) progressive, progressive relapsing, or worsening relapsing-remitting disease (i.e., patients whose neurological status is significantly abnormal between relapses).
The overall objective of this study is to collect data relevant to the tolerability of Novantrone® therapy in patients with multiple sclerosis (MS) using dosing and monitoring recommendations specified in the package insert.
Тип исследования
Регистрация (Действительный)
Контакты и местонахождение
Места учебы
-
-
Kentucky
-
Lexington, Kentucky, Соединенные Штаты, 40504-3276
- Registrat Inc
-
-
Критерии участия
Критерии приемлемости
Возраст, подходящий для обучения
Принимает здоровых добровольцев
Полы, имеющие право на обучение
Метод выборки
Исследуемая популяция
Описание
Inclusion Criteria:
- To be eligible for inclusion into this study, the subjects must fulfill all of the following criteria:
- Platelet count >100,000 cells/µL
- Granulocyte count > 2000 cells/µL
- Age 18-65 years
- Negative pregnancy test for female patients who are biologically capable of becoming pregnant, even if they are taking birth control
- For patients of reproductive age, agreement to practice effective contraception throughout the study and for 6 months following the last administration of Novantrone®
- Signed Inform Consent.
Exclusion Criteria:
- To be eligible for inclusion in this study the subjects must not meet any of the following criteria:
- Presence of cardiac risk factors:
- History of congestive heart failure
- LVEF < 50% determined by echocardiography or MUGA
- Previous treatment with Novantrone®, other anthracenediones, or anthracyclines
- Prior mediastinal radiotherapy or total lymphoidal irradiation
- AST, ALT, bilirubin > 2x upper limits of normal
- Severe untreated infection (including current urinary tract infection)
- Nursing or pregnant women)
Учебный план
Как устроено исследование?
Детали дизайна
Что измеряет исследование?
Первичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
---|---|---|
Congestive Heart Failure (Treatment Phase)
Временное ограничение: up to 36 months
|
Number of patients experiencing congestive heart failure during the treatment phase of the trial
|
up to 36 months
|
Congestive Heart Failure (Annual Follow-Up Phase)
Временное ограничение: up to 5 years
|
Number of patients experiencing congestive heart failure during the annual follow-up phase of the trial
|
up to 5 years
|
Left Ventricular Ejection Fraction (Treatment Phase)
Временное ограничение: up to 36 months
|
Number of patients with left ventricular ejection fraction test results that decreased below 50% during the treatment phase of the trial
|
up to 36 months
|
Left Ventricular Ejection Fraction (Annual Follow-Up Phase)
Временное ограничение: up to 5 years
|
Number of patients with left ventricular ejection fraction test results that decreased below 50% during the annual follow-up phase of the trial
|
up to 5 years
|
Serious Infections (Treatment Phase)
Временное ограничение: up to 36 months
|
Number of serious infections during the treatment phase of the trial
|
up to 36 months
|
Serious Infections (Annual Follow-Up Phase)
Временное ограничение: up to 5 years
|
Number of serious infections during the annual follow-up phase of the trial
|
up to 5 years
|
IV Antibiotics (Individual Drugs Unspecified) Utilized Due to Serious Infection (Treatment Phase)
Временное ограничение: up to 36 months
|
Number of subjects in whom IV antibiotics were utilized due to serious infection during the treatment phase
|
up to 36 months
|
IV Antibiotics (Individual Drugs Unspecified) Utilized Due To Serious Infection (Annual Follow-Up Phase)
Временное ограничение: up to 5 years
|
Number of subjects in whom IV antibiotics were utilized due to serious infection during the annual follow-up phase
|
up to 5 years
|
Severe Neutropenia (Treatment Phase)
Временное ограничение: up to 36 months
|
Number of infections associated with severe neutropenia at onset during the treatment phase
|
up to 36 months
|
Severe Neutropenia (Annual Follow-Up Phase)
Временное ограничение: up to 5 years
|
Number of infections associated with severe neutropenia at onset during the annual follow-up phase
|
up to 5 years
|
Clinical Relapses (Treatment Phase)
Временное ограничение: up to 36 months
|
Number of clinical relapses reported during the treatment phase of the trial
|
up to 36 months
|
Clinical Relapses (Annual Follow-Up Phase)
Временное ограничение: up to 5 years
|
Number of clinical relapses reported during the annual follow-up phase of the trial
|
up to 5 years
|
Symptomatic CHF, Left Ventricular Ejection Fraction - Prior to Each Dose • Serious Infections, IV Antibiotics, or Assoc w/ Severe Neutropenia-evaluated. Novantrone Admin - Per PI • SAE, Clinical Relapses
Временное ограничение: up to 5 years
|
Outcomes are presented separately above apart from adverse events which are presented in the adverse event section
|
up to 5 years
|
Соавторы и исследователи
Спонсор
Следователи
- Директор по исследованиям: Randy Bennett, EMD Serono
Даты записи исследования
Изучение основных дат
Начало исследования
Первичное завершение (Действительный)
Завершение исследования (Действительный)
Даты регистрации исследования
Первый отправленный
Впервые представлено, что соответствует критериям контроля качества
Первый опубликованный (Оценивать)
Обновления учебных записей
Последнее опубликованное обновление (Оценивать)
Последнее отправленное обновление, отвечающее критериям контроля качества
Последняя проверка
Дополнительная информация
Термины, связанные с этим исследованием
Дополнительные соответствующие термины MeSH
Другие идентификационные номера исследования
- 24293
- 19-297
Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .